The excitement around Moderna’s cancer vaccine is cooling. Here’s why.

Feed excerpt — reported by MarketWatch

Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at MarketWatch →

View MAP Context →